Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 6
2018 1
2020 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251359 Free article. Clinical Trial.
The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annua …
The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91 …
36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.
Bateman RM, Sharpe MD, Jagger JE, Ellis CG, Solé-Violán J, López-Rodríguez M, Herrera-Ramos E, Ruíz-Hernández J, Borderías L, Horcajada J, González-Quevedo N, Rajas O, Briones M, Rodríguez de Castro F, Rodríguez Gallego C, Esen F, Orhun G, Ergin Ozcan P, Senturk E, Ugur Yilmaz C, Orhan N, Arican N, Kaya M, Kucukerden M, Giris M, Akcan U, Bilgic Gazioglu S, Tuzun E, Riff R, Naamani O, Douvdevani A, Takegawa R, Yoshida H, Hirose T, Yamamoto N, Hagiya H, Ojima M, Akeda Y, Tasaki O, Tomono K, Shimazu T, Ono S, Kubo T, Suda S, Ueno T, Ikeda T, Hirose T, Ogura H, Takahashi H, Ojima M, Kang J, Nakamura Y, Kojima T, Shimazu T, Ikeda T, Suda S, Izutani Y, Ueno T, Ono S, Taniguchi T, O M, Dinter C, Lotz J, Eilers B, Wissmann C, Lott R, Meili MM, Schuetz PS, Hawa H, Sharshir M, Aburageila M, Salahuddin N, Chantziara V, Georgiou S, Tsimogianni A, Alexandropoulos P, Vassi A, Lagiou F, Valta M, Micha G, Chinou E, Michaloudis G, Kodaira A, Ikeda T, Ono S, Ueno T, Suda S, Izutani Y, Imaizumi H, De la Torre-Prados MV, Garcia-De la Torre A, Enguix-Armada A, Puerto-Morlan A, Perez-Valero V, Garcia-Alcantara A, Bolton N, Dudziak J, Bonney S, Tridente A, Nee P, Nicolaes G, Wiewel M, Schultz M, Wildhag… See abstract for full author list ➔ Bateman RM, et al. Crit Care. 2016 Apr 20;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6. Crit Care. 2016. PMID: 27885969 Free PMC article.
Reis P181 - Missing the "I" in MUDPILES - a rare cause of high anion gap metabolic acidosis (HAGMA) C. P. Lee, X. L. Lin, C. Choong , K. M. Eu, W. Y. Sim , K. S. Tee, J. ...J. Capponi, P. P. Chan P195 - Observations in early vs. late use of cyto …
Reis P181 - Missing the "I" in MUDPILES - a rare cause of high anion gap metabolic acidosis (HAGMA) C. P. Lee, X. L. Lin, C. Choong , …
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Yusuf S, et al. N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2. N Engl J Med. 2016. PMID: 27040132 Free article. Clinical Trial.
The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consis …
The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo grou …
Management of Coronary Disease in Patients with Advanced Kidney Disease.
Bangalore S, Maron DJ, O'Brien SM, Fleg JL, Kretov EI, Briguori C, Kaul U, Reynolds HR, Mazurek T, Sidhu MS, Berger JS, Mathew RO, Bockeria O, Broderick S, Pracon R, Herzog CA, Huang Z, Stone GW, Boden WE, Newman JD, Ali ZA, Mark DB, Spertus JA, Alexander KP, Chaitman BR, Chertow GM, Hochman JS; ISCHEMIA-CKD Research Group. Bangalore S, et al. N Engl J Med. 2020 Apr 23;382(17):1608-1618. doi: 10.1056/NEJMoa1915925. Epub 2020 Mar 30. N Engl J Med. 2020. PMID: 32227756 Free PMC article. Clinical Trial.
RESULTS: At a median follow-up of 2.2 years, a primary outcome event had occurred in 123 patients in the invasive-strategy group and in 129 patients in the conservative-strategy group (estimated 3-year event rate, 36.4% vs. 36.7%; adjusted hazard ratio, 1.01; 95% confidence inter …
RESULTS: At a median follow-up of 2.2 years, a primary outcome event had occurred in 123 patients in the invasive-strategy group and in 129 …
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.
Patel A, Bhatt N, Prakash SS, Biswas G, Nagarkar R, Roy B, Samal P, Agrawal N, Meshram S, Kaushal A, Satheesh CT, Wategaonkar R, Thiagarajan KV, Jain K, Vijayaveeran P, Mukherjee K, Singh K, Patil T, Jain A, Dolai TK, Jain M, Hingmire S, Gupta TC, Lakshmaiah KC, Rajamanickam D, Nemade B, Goyal V, Mahato P, Mendiratta SK, Doshi M. Patel A, et al. Cancer Chemother Pharmacol. 2023 Jun;91(6):457-468. doi: 10.1007/s00280-023-04530-x. Epub 2023 Apr 24. Cancer Chemother Pharmacol. 2023. PMID: 37093266 Free PMC article. Clinical Trial.
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S; HOPE-3 Investigators. Lonn EM, et al. N Engl J Med. 2016 May 26;374(21):2009-20. doi: 10.1056/NEJMoa1600175. Epub 2016 Apr 2. N Engl J Med. 2016. PMID: 27041480 Free article. Clinical Trial.
The first coprimary outcome occurred in 260 participants (4.1%) in the active-treatment group and in 279 (4.4%) in the placebo group (hazard ratio, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P=0.40); the second coprimary outcome occurred in 312 participants (4.9%) a …
The first coprimary outcome occurred in 260 participants (4.1%) in the active-treatment group and in 279 (4.4%) in the placebo group (hazard …
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G; HOPE-3 Investigators. Yusuf S, et al. N Engl J Med. 2016 May 26;374(21):2032-43. doi: 10.1056/NEJMoa1600177. Epub 2016 Apr 2. N Engl J Med. 2016. PMID: 27039945 Free article. Clinical Trial.
The first coprimary outcome occurred in 113 participants (3.6%) in the combined-therapy group and in 157 (5.0%) in the dual-placebo group (hazard ratio, 0.71; 95% confidence interval [CI], 0.56 to 0.90; P=0.005). The second coprimary outcome occurred in 136 participants (4 …
The first coprimary outcome occurred in 113 participants (3.6%) in the combined-therapy group and in 157 (5.0%) in the dual-placebo group (h …
Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States.
Jezmir JL, Bharadwaj M, Chaitoff A, Diephuis B, Crowley CP, Kishore SP, Goralnick E, Merriam LT, Milliken A, Rhee C, Sadovnikoff N, Shah SB, Gupta S, Leaf DE, Feldman WB, Kim EY; STOP-COVID Investigators. Jezmir JL, et al. Cell Rep Med. 2021 Sep 21;2(9):100376. doi: 10.1016/j.xcrm.2021.100376. Epub 2021 Jul 28. Cell Rep Med. 2021. PMID: 34337554 Free PMC article.
Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients.
Krishnamoorthy S, Rajan R, Banerjee M, Kumar H, Sarma G, Krishnan S, Sarma S, Kishore A. Krishnamoorthy S, et al. Parkinsonism Relat Disord. 2016 Sep;30:13-7. doi: 10.1016/j.parkreldis.2016.06.005. Epub 2016 Jun 15. Parkinsonism Relat Disord. 2016. PMID: 27325396
RESULTS: Multivariate regression analysis revealed that DRD3 p.Ser9Gly (rs6280) heterozygous variant CT (OR = 2.22, 95% CI: 1.03-4.86, p = 0.041), higher daily Levodopa equivalent doses (LED) of drugs (for 100 mg LED, OR = 1.14, 95% CI: 1.01-1.29, p = 0.041), …
RESULTS: Multivariate regression analysis revealed that DRD3 p.Ser9Gly (rs6280) heterozygous variant CT (OR = 2.22, 95% CI: 1.03-4.86 …
Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22 - April 30, 2020.
ICMR COVID Study Group (In alphabetical order: Priya Abraham†, Neeraj Aggarwa l2, Giridhara R. Babu 7, Suganya Barani 8, Balram Bhargava 4, Tarun Bhatnagar 8, Ajay Singh Dhama 3, Raman R. Gangakhedkar 2, Sidhartha Giri 2, Nivedita Gupta 2, Karishma K. Kurup 5, Ponnaiah Manickam 9, Manoj Murhekar ††, Varsha Potdar 1, Ira Praharaj 2, Kiran Rade 6, D.C.S. Reddy 11, V. Saravanakumar 10, Naman Shah 12, Harpreet Singh 3, Jeromie Wesley Vivian Thangaraj 8, Naveen Yadav 8), COVID Epidemiology & Data Management Team @, COVID Laboratory Team*, VRDLN Team$; @COVID Epidemiology & Data Management Team (in alphabetical order): Tanu Anand, Harish Kumar Butollia, Pranab Chatterjee, Himanshu Chauhan, R Deepa, Amirthammal Gunasekaran, Daisy A John, Shashi Kant, Sanket Kulkarni, Vinit Kumar, JP Muliyil, Ravindra Mohan Pandey, Swarup Sarkar, Sujeet Singh, Sanjay Zodpey; *COVID Laboratory Team (in alphabetical order): Srima Adhikari, Jyotsna Agarwal, Naveen KumarAgarwal, Saurabh G Agarwal, Prerna Aggarwal, Anurag Agrawal, Arti Agrawal, Safaa Muneer Ahmed, G Ambernath, Nitin Ambhore, VP Amudha, Sohini Arora, Ashok, Anita, Awanti, Veer Badriyah TA, Amrita Kumari B, Maneesh Bagai, Dipa Baido, Bai… See abstract for full author list ➔ ICMR COVID Study Group (In alphabetical order: Priya Abraham†, Neeraj Aggarwa l2, Giridhara R. Babu 7, Suganya Barani 8, Balram Bhargava 4, Tarun Bhatnagar 8, Ajay Singh Dhama 3, Raman R. Gangakhedkar 2, Sidhartha Giri 2, Nivedita Gupta 2, Karishma K. Kurup 5, Ponnaiah Manickam 9, Manoj Murhekar ††, Varsha Potdar 1, Ira Praharaj 2, Kiran Rade 6, D.C.S. Reddy 11, V. Saravanakumar 10, Naman Shah 12, Harpreet Singh 3, Jeromie Wesley Vivian Thangaraj 8, Naveen Yadav 8), COVID Epidemiology & Data Management Team @, COVID Laboratory Team*, VRDLN Team$, et al. Indian J Med Res. 2020 May;151(5):424-437. doi: 10.4103/ijmr.IJMR_1896_20. Indian J Med Res. 2020. PMID: 32611914 Free PMC article.
12 results